Flibanserin for Hypoactive Sexual Desire Disorder

Efficacy and Approval

• The American College of Obstetricians and Gynecologists acknowledges that flibanserin received FDA approval in August 2015 for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women 1
• Flibanserin demonstrates modest efficacy, resulting in approximately 1 additional satisfying sexual event every 2 months compared to placebo in premenopausal women with HSDD 1